 |
 |
 |
 |
 |
 |
 |
 |
Potentia is an early stage biotechnology company focused on developing innovative therapeutics, primarily in the area of age-related macular degeneration and other inflammatory ocular diseases. Potentia assembles its pipeline of anti-inflammatory products through a combination of in-licensing of preclinical compounds and in-house research and development.
The safety of Potentia's POT-4, a small cyclic synthetic peptide, is being confirmed by the ASaP Phase I clinical trial conducted wet AMD patients.
The trial is ongoing at 6 sites across the United State.
more info on POT-4 »
- September 2008 Potentia Pharmaceuticals to present ASaP clinical trial data during the AAO annual meeting
more » - September 2008 Potentia Pharmaceuticals announces positive safety data and study expansion in Phase I Trial for lead drug candidate POT-4
more » - September 2008 Potentia featured in BioCentury article "The eye have it"
more » - September 2008 Potentia poises for validation in complement inhibition in AMD
more »
